Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis


23 Nov 2019


Poster display session


End-of-Life Care

Tumour Site


Pradip Bhandari


P. Bhandari

Author affiliations

  • Clinical Oncology, NAMS, Bir Hospital, 44600 - Kathmandu/NP


Abstract YO27

Case summary

Whole Brain Radiotherapy plays a pivoted role in brain metastases. There is controversy regarding the radiotherapeutics dose fractionation in brain metastasis. 30 Gray in 10 fractions in 2 weeks in the standard regimen in most centers. Regarding the extraordinary poor survival prognosis of patients with brain metastasis, 20 Gray in 5 fractions over 1 week would be preferable. An observational comparative analytical study was conducted in National Academy of Medical Sciences (NAMS) Bir Hospital after ethical approval from the institutional review board of NAMS. Patients were randomized into two group one with 20 Gray in 5 fraction over one week and other with the 30Gray in 10 Fraction over 2 weeks. A total number of 55 patients were enrolled in the study. Assessment of clinical symptoms was done using Common terminology Criteria for Adverse Events (CTCAE), before treatment, just after treatment and 6 weeks of treatment. Response evaluation criteria in solid tumors (RECIST) was used to access the treatment response in terms of local control. Acute toxicity of the patients were assess during treatment and then followed for 6 weeks and graded according to Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring. Of the 55 patients enrolled, in 20Gray/5# (n=28) and 30Gray/10# (n=26) groups, all participants in the study received the planned treatment of radiotherapy. Local control with complete or partial response was 63% in 20Gray v 48% in 30Gray (p = 0.722). Six month survival was 29.1% in 20Gray/5# v 23.6% in 30Gray/10# (p = 0.504). Objective Responsive of Headache was 53% v 52% (p= 0.469), vomiting 43% v 55%,(p=0.956),Seizure 11.7% v 3.7% (p = 0.979), focal weakness 21.3% v 4.4% (p=0.249), ataxia1 4.3% v 3.7% (p=0.281), speech disorder 3.5% v 7.4% (p=0.147), acute toxicities of grade 2 and grade 3 were acceptable in both Groups, nausea 9.1% v 9.1% ( p =0.907), vomiting 1.9% v 3.7% (p=0.199) , headache 1.9% v 3.7% (p=0.696) and Dermatitis 5.7% v 5.7% (p =0.140) 20Gray in 5fractions and 30Gray in 10 Fractions are equally effective and feasible as statistically insignificant difference in the response rate and acute toxicities were observed in the two groups

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.